Estrevagel (Estradiol Hemihydrate)

Adult dose

(Tablets) Administer 1 or 2 mg of estradiol orally once daily without interruption. If adverse reactions occur at a 2 mg dose, reduce to 1 mg. (Gel) The amount applied at one time corresponds to 0.75 mg of estradiol (gel volume 1.25 g); 1.5 mg (2 compressions) is to be administered daily for 24 to 28 days. The dosage can be adjusted based on clinical symptoms. (Estrava gel)

This drug may increase the risk of endometrial hyperplasia and endometrial cancer in women post-menopause; thus, if the uterus is still present, progestogens should be taken as directed by a doctor. Moreover, long-term use of this drug for more than five years may slightly increase the risk of breast cancer, making regular breast examinations and self-assessments necessary. Patients with breast cancer or bone metastatic disease may experience severe hypercalcemia if this drug is used, necessitating its discontinuation. This drug should not be used by individuals with specific conditions or diseases such as breast cancer, endometrial cancer, liver disease, cardiovascular disease, thromboembolism, and pregnant women. Before use, it is essential to review personal and family medical histories, and to closely monitor health status through regular check-ups during treatment. This medication may increase the risk of cardiovascular diseases such as thrombosis, stroke, and myocardial infarction, so patients with these risk factors need to be particularly cautious. In case of overdose, symptoms such as nausea, vomiting, and breast tension may occur, and as there is no specific antidote, symptomatic treatment is necessary. This drug should not be administered to women who are pregnant or could become pregnant, or to breastfeeding mothers, as it may harm the fetus during pregnancy. Additionally, this drug may interact with other medications, so anyone taking other drugs should inform their healthcare provider. When applying this medication, skin irritation or allergic reactions may occur, so the application area should be cleaned and hands washed thoroughly after use. If surgery is expected or long periods of immobility are anticipated, it is recommended to discontinue use of this drug 4 to 6 weeks before surgery and to resume after recovery. Hormone replacement therapy should be utilized at the minimum effective dose to relieve symptoms, with a regular assessment of risks and benefits to decide whether to continue treatment. This drug does not serve as a contraceptive and will not prevent pregnancy; if pregnancy is confirmed during treatment, use should be discontinued immediately. Lastly, this drug should be stored out of reach of children, kept in its original container, and maintained at room temperature, below 25 degrees.

Serious side effects

• Hives
• severe swelling (edema)
• angioedema
• chest tightness
• difficulty breathing
• thromboembolism
• deep vein thrombosis
• pulmonary embolism
• anaphylaxis
• significant increase in blood pressure

Mild side effects

• Depression
• headache
• visual disturbances
• abdominal pain
• nausea
• dyspepsia
• vomiting
• bloating
• abdominal distension
• gallstones

This drug is sensitive to light; therefore, it should be stored in an opaque container. It is also important to keep it in a sealed container to prevent air exposure while storing it at room temperature. This helps maintain the drug's efficacy and safety.

Appearance

A translucent gel that is dispensed in specific amounts from a white, sealed, opaque container

Package unit

50 grams/tube